Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20189091 | 1.00 | TP53 (0.47) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL20188956 | 1.00 | TP53 (0.47) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL27857861 | 0.76 | EPHX1 (0.38) | TP53EPHX1CA1CA2DPP4 | |
| SCHEMBL6227823 | 0.73 | TP53 (0.64) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL14463100 | 0.73 | TP53 (0.64) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5185757 | 0.73 | TP53 (0.64) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL10324078 | 0.72 | TP53 (0.62) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL8640532 | 0.71 | SHBG (0.35) | SMN1; SMN2EPHX1CA1CA2ALDH1A1 | |
| SCHEMBL4977295 | 0.70 | TP53 (0.67) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL27857857 | 0.69 | EPHX1 (0.35) | TP53EPHX1CA1CA2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3541805-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018097945-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | TP53 4741/4885KDM4E 4398/4885GMNN 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.